Stream
Stories
-
FDA partially grants petition to remove methylene chloride as color additive diluent
The order removes a solvent used as a diluent in inks for marking fruit and vegetables, effective January 11, 2027. Requests to remove ethylene dichloride and trichloroethylene from extraction solvents for annatto, paprika, and turmeric were denied because residues would be impurities not covered by the Delaney Clause.
-
Survodutide shows no increased cardiovascular risk in obesity trial
The authors reported that in the SYNCHRONIZE-CVOT phase 3 trial, 136 of 3671 participants receiving survodutide experienced the primary composite endpoint versus 76 of 1836 receiving placebo (HR 0·89 [95% CI 0·67-1·18]). Gastrointestinal adverse events were more frequent with survodutide, with nausea in 48·0%-49·0% and vomiting in 31·7%-34·0% of participants.
-
FDA approves Sunharbo for secondary stroke prevention
The FDA approved Sunharbo (asundexian) 50 mg tablets on November 09, 2026 for adults at high risk of stroke after a mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA. The OCEANIC-STROKE phase 3 study enrolled 12,327 participants and found Sunharbo 50 mg once daily significantly reduced the risk of ischemic stroke by 26 % compared to placebo over a median treatment of 14.2 months.
-
PharmaLogic to acquire Lantheus CDMO business and Springfield facility
PharmaLogic announced a definitive agreement to acquire Lantheus' CDMO business and the Springfield, New Jersey manufacturing facility, expanding its U.S. radiopharmaceutical manufacturing capacity. The transaction includes a long-term supply agreement under which Agilera will manufacture lutetium Lu-177 dotatate for Lantheus.
-
Johnson & Johnson FDA grants accelerated approval for RYBREVANT FASPRO in head and neck cancer
The FDA granted accelerated approval for RYBREVANT FASPRO as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval was based on the Phase 1b/2 OrigAMI-4 trial, in which the confirmed overall response rate was 42 percent per blinded independent central review.
-
Anaheim Bio lève 40 millions d'euros en série A
Anaheim Bio a annoncé un financement de série A sursouscrit de 40 millions d'euros, assuré par Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest et Thuja Capital. Le capital permettra de franchir les études préparatoires à l'IND et d'entrer en phase 1 pour l'ANA-1, un candidat thérapeutique contre la maladie de dépôt de pyrophosphate de calcium.
-
CSPC Megalith Biopharmaceutical registers Phase III trial of enlonstobart with SYS6010
The trial plans to enroll 585 participants, beginning on December 30, 2026, with a primary completion date of December 30, 2029. It is a randomized, controlled, double-blind, multicenter Phase III study evaluating the efficacy and safety of enlonstobart with or without SYS6010 in participants with pathologically residual esophageal squamous cell carcinoma after complete surgical resection.
-
Ascendis Pharma registers Phase 3 trial of navepegritide and lonapegsomatropin in achondroplasia
The study, led by Ascendis Pharma A/S, plans to enroll 144 participants and start in November 2026. It compares dual therapy with navepegritide and lonapegsomatropin to navepegritide monotherapy and lonapegsomatropin monotherapy in children and adolescents with achondroplasia.
-
Hoffmann-La Roche posts results of Phase III tiragolumab trial in NSCLC
The study, completed with 620 participants, compared tiragolumab plus atezolizumab to placebo plus atezolizumab in patients with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer. Primary completion occurred on December 30, 2025, and the trial was registered as NCT04294810.
-
Johnson & Johnson reports 73% PSA response rate in Phase 1 study
Johnson & Johnson said that 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in PSA, and 47 percent (7 of 15 patients) achieved reductions of at least 90 percent. The company noted no Grade 3 or higher treatment-related adverse events in this early analysis.
-
Johnson & Johnson releases new Phase 2 nipocalimab data in Sjögren's disease
Johnson & Johnson said the Phase 2 DAHLIAS study found that mouth dryness was the most important symptom to improve, with 96% of patients citing it. The study also reported that at least 50% improvement in objective salivary flow was observed in more than twice as many patients receiving 15 mg/kg nipocalimab compared with placebo (33% versus 16%) at Week 24.
-
Johnson & Johnson reports ICOTYDE achieves 58% ACR20 response in biologic-naïve psoriatic arthritis
The Phase 3 ICONIC-PsA 1 study met its primary endpoint, with 58% of ICOTYDE-treated patients achieving an ACR20 response versus 41% of placebo at Week 16. Safety data through Week 24 showed no new safety signals and were consistent with the established safety profile of ICOTYDE.